QC
IBRX icon

Quent Capital’s ImmunityBio IBRX Stock Holding History

Quent Capital’s Portfolio IBRX Stock Details IBRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$7.13K Hold
815
– – ﹤0.01% 1312
2026
Q1 		$6.25K Buy
815
+364
+81% +$2.49K ﹤0.01% 1242
2025
Q4 		$893 Buy
+451
New +$1.02K ﹤0.01% 1473
2024
Q2 		– Sell
-1,824
Closed -$9.79K – 1361
2024
Q1 		$9.79K Hold
1,824
– – ﹤0.01% 1023
2023
Q4 		$9.16K Sell
1,824
-5
-0.3% -$16 ﹤0.01% 988
2023
Q3 		$3.09K Buy
1,829
+1,392
+319% +$2.79K ﹤0.01% 1130
2023
Q2 		$1.22K Buy
437
+35
+9% +$99 ﹤0.01% 1228
2023
Q1 		$732 Buy
402
+89
+28% +$277 ﹤0.01% 1253
2022
Q4 		$1.59K Buy
+313
New +$1.72K ﹤0.01% 1177

Other funds holding IBRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Quent Capital's IBRX Position: Q2 2026 in Review

Quent Capital held its ImmunityBio (IBRX) position steady in Q2 2026 at 815 shares worth $7.13K. The position accounts for ﹤0.01% of the portfolio, ranked #1312.

Quent Capital first reported a position in IBRX in Q4 2022 and has held it in 9 quarters since. The position peaked at $9.79K in Q1 2024. 405 funds tracked by Wall St. Rank hold IBRX as of Q2 2026.

  • Quent Capital held 815 shares of ImmunityBio worth $7.13K as of Q2 2026.
  • Quent Capital left its ImmunityBio share count unchanged in Q2 2026.
  • ImmunityBio made up ﹤0.01% of Quent Capital's portfolio in Q2 2026, its #1312 holding.
  • Quent Capital first reported a position in ImmunityBio in Q4 2022 and has held it in 9 quarters since.
  • Quent Capital's ImmunityBio position peaked at $9.79K in Q1 2024.
  • 405 funds tracked by Wall St. Rank held ImmunityBio as of Q2 2026.

Based on Quent Capital's 13F filing for Q2 2026, filed 7 Aug 2026.